Aspirin acetylates multiple cellular proteins in HCT-116 colon cancer cells: Identification of novel targets

International Journal of Oncology

Volumn 39, Issue 5, 2011, Pages 1273-1283

  Marimuthu, Srinivasan ^a   Chivukula, Raghavender S V ^a   Alfonso, Lloyd F ^b   Moridani, Majid ^a   Hagen, Fred K ^c   Bhat, G Jayarama ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b D'YOUVILLE COLLEGE   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Acetylation; Anti cancer effect; Aspirin; Glycolytic pathway; Metabolic enzymes; Pentose phosphate pathway

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CELL PROTEIN; CYTOSKELETON PROTEIN; ENOLASE; FRUCTOSE BISPHOSPHATE ALDOLASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HISTONE; LACTATE DEHYDROGENASE; MITOCHONDRIAL PROTEIN; PYRUVATE KINASE; RIBOSOME PROTEIN; TRANSKETOLASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; COLON CANCER; CONTROLLED STUDY; DRUG ACETYLATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; MASS SPECTROMETRY; MOLECULAR WEIGHT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PROCESSING; RNA SYNTHESIS;

ACETYLATION; ASPIRIN; COLONIC NEOPLASMS; ENZYME ACTIVATION; GLUCOSEPHOSPHATE DEHYDROGENASE; GLYCOSYLATION; HCT116 CELLS; HT29 CELLS; HUMANS; LACTATE DEHYDROGENASES; MASS SPECTROMETRY; METABOLIC NETWORKS AND PATHWAYS; PENTOSE PHOSPHATE PATHWAY; PHOSPHORYLATION; PROTEINS; PYRUVATE KINASE;

EID: 80053205123     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1113     Document Type: Article

References (51)

1. Flossmann E and Rothwell PM: Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369: 1603-1613, 2007. (Pubitemid 46710123)
2. Chan AT and Giovannucci EL: Primary prevention of colorectal cancer. Gastroenterology 138: 2029-2043, 2010.
3. Harris RE, Beebe-Donk J, Doss H and Burr Doss D: Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 13: 559-583, 2005.
4. Luciani MG, Campregher C and Gasche C: Aspirin blocks proliferation in colon cells by inducing a G1 arrest and apoptosis through activation of the checkpoint kinase ATM. Carcinogenesis 28: 2207-2217, 2007. (Pubitemid 47543383)
5. Hanif R, Pittas A, Feng Y, et al: Effects of nonsteroidal antiinflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 52: 237-245, 1996. (Pubitemid 26233752)
6. Chan AT, Ogino S and Fuchs CS: Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302: 649-658, 2009.
7. Kopp E and Ghosh S: Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265: 956-959, 1994.
8. Roth GJ, Machuga ET and Ozols J: Isolation and covalent structure of the aspirin-modified, active-site region of prostaglandin synthetase. Biochemistry 22: 4672-4675, 1983. (Pubitemid 13016991)
9. Vane JR and Botting RM: The mechanism of action of aspirin. Thromb Res 110: 255-258, 2003. (Pubitemid 37329821)
10. Oshima M, Dinchuk JE, Kargman SL, et al: Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87: 803-809, 1996. (Pubitemid 26404280)
11. Soh JW and Weinstein IB: Role of COX-independent targets of NSAIDs and related compounds in cancer prevention and treatment. Prog Exp Tumor Res 37: 261-285, 2003.
12. Yin MJ, Yamamoto Y and Gaynor RB: The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396: 77-80, 1998. (Pubitemid 28520452)
13. Schwenger P, Bellosta P, Vietor I, Basilico C, Skolnik EY and Vilcek J: Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc Natl Acad Sci USA 94: 2869-2873, 1997. (Pubitemid 27157231)
14. Martinez ME, O'Brien TG, Fultz KE, et al: Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci USA 100: 7859-7864, 2003. (Pubitemid 36760060)
15. Caterson RJ, Duggin GG, Horvath J, Mohandas J and Tiller D: Aspirin, protein transacetylation and inhibition of prostaglandin synthetase in the kidney. Br J Pharmacol 64: 353-358, 1978. (Pubitemid 9060213)
16. Green FA and Jung CY: Acetylation of erythrocytic membrane peptides by aspirin. Transfusion 21: 55-58, 1981. (Pubitemid 12207712)
17. Alfonso LF, Srivenugopal KS, Arumugam TV, Abbruscato TJ, Weidanz JA and Bhat GJ: Aspirin inhibits camptothecin-induced p21CIP1 levels and potentiates apoptosis in human breast cancer cells. Int J Oncol 34: 597-608, 2009.
18. Alfonso LF, Srivenugopal KS and Bhat GJ: Does aspirin acetylate multiple cellular proteins? (Review). Mol Med Rep 2: 533-537, 2009.
19. Choudhary C, Kumar C, Gnad F, et al: Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325: 834-840, 2009.
20. Wang Q, Zhang Y, Yang C, et al: Acetylation of metabolic enzymes coordinates carbon source utilization and metabolic flux. Science 327: 1004-1007, 2010.
21. Zhao S, Xu W, Jiang W, et al: Regulation of cellular metabolism by protein lysine acetylation. Science 327: 1000-1004, 2010.
22. Pinckard RN, Hawkins D and Farr RS: In vitro acetylation of plasma proteins, enzymes and DNA by aspirin. Nature 219: 68-69, 1968.
23. Warburg O: On the origin of cancer cells. Science 123: 309-314, 1956.
24. Mazurek S: Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol (In press).
25. Cairns RA, Harris IS and Mak TW: Regulation of cancer cell metabolism. Nat Rev Cancer 11: 85-95, 2011.
26. Roberts MS, Rumble RH, Wanwimolruk S, Thomas D and Brooks PM: Pharmacokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease. Eur J Clin Pharmacol 25: 253-261, 1983. (Pubitemid 13000516)
27. Hitosugi T, Kang S, Vander Heiden MG, et al: Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal 2: ra73, 2009.
28. Christofk HR, Vander Heiden MG, Harris MH, et al: The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-233, 2008. (Pubitemid 351380249)
29. Le A, Cooper CR, Gouw AM, et al: Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 107: 2037-2042, 2010.
30. Basu A, Rose KL, Zhang J, et al: Proteome-wide prediction of acetylation substrates. Proc Natl Acad Sci USA 106: 13785-13790, 2009.
31. Ramos-Montoya A, Lee WN, Bassilian S, et al: Pentose phosphate cycle oxidative and nonoxidative balance: A new vulnerable target for overcoming drug resistance in cancer. Int J Cancer 119: 2733-2741, 2006. (Pubitemid 44846223)
32. Boros LG, Lee PW, Brandes JL, et al: Nonoxidative pentose phosphate pathways and their direct role in ribose synthesis in tumors: is cancer a disease of cellular glucose metabolism? Med Hypotheses 50: 55-59, 1998. (Pubitemid 28046401)
33. Rowland M, Riegelman S, Harris PA and Sholkoff SD: Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J Pharm Sci 61: 379-385, 1972.
34. Liyasova MS, Schopfer LM and Lockridge O: Reaction of human albumin with aspirin in vitro: mass spectrometric identification of acetylated lysines 199, 402, 519, and 545. Biochem Pharmacol 79: 784-791, 2010.
35. Needs CJ and Brooks PM: Clinical pharmacokinetics of the salicylates. Clin Pharmacokinet 10: 164-177, 1985. (Pubitemid 15104999)
36. Cherian M and Abraham EC: Glycation of human lens crystallins: effect of age and aspirin treatment. Ophthalmic Res 25: 349-354, 1993. (Pubitemid 23355605)
37. Mathupala SP, Ko YH and Pedersen PL: Hexokinase-2 bound to mitochondria: cancer's stygian link to the 'Warburg effect' and a pivotal target for effective therapy. Semin Cancer Biol 19: 17-24, 2009.
38. Zhou W, Capello M, Fredolini C, et al: Mass spectrometry analysis of the post-translational modifications of alpha-enolase from pancreatic ductal adenocarcinoma cells. J Proteome Res 9: 2929-2936, 2010.
39. Vizan P, Alcarraz-Vizan G, Diaz-Moralli S, Solovjeva ON, Frederiks WM and Cascante M: Modulation of pentose phosphate pathway during cell cycle progression in human colon adenocarcinoma cell line HT29. Int J Cancer 124: 2789-2796, 2009.
40. Tian WN, Braunstein LD, Pang J, et al: Importance of glucose- 6-phosphate dehydrogenase activity for cell growth. J Biol Chem 273: 10609-10617, 1998. (Pubitemid 28227673)
41. Board M, Humm S and Newsholme EA: Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells. Biochem J 265: 503-509, 1990. (Pubitemid 20041995)
42. Jiang P, Du W, Wang X, et al: p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol 13: 310-316, 2011.
43. Tennant DA, Duran RV and Gottlieb E: Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10: 267-277, 2010.
44. Boros LG, Puigjaner J, Cascante M, et al: Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Res 57: 4242-4248, 1997. (Pubitemid 27413432)
45. Rais B, Comin B, Puigjaner J, et al: Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's tumor cells through inhibition of the pentose cycle. FEBS Lett 456: 113-118, 1999. (Pubitemid 29339052)
46. Yang Y, Rao R, Shen J, et al: Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Res 68: 4833-4842, 2008.
47. Guzman-Aranguez A, Olmo N, Turnay J, et al: Differentiation of human colon adenocarcinoma cells alters the expression and intracellular localization of annexins A1, A2, and A5. J Cell Biochem 94: 178-193, 2005. (Pubitemid 41420335)
48. Lane AA and Chabner BA: Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27: 5459-5468, 2009.
49. Spange S, Wagner T, Heinzel T and Kramer OH: Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 41: 185-198, 2009.
50. Kouzarides T: Acetylation: a regulatory modification to rival phosphorylation? EMBO J 19: 1176-1179, 2000.
51. Norvell A and McMahon SB: Cell biology. Rise of the rival. Science 327: 964-965, 2010.